Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|September 14, 2022

Dr. Casey Kowalik on why it’s a “great time to be a woman in urology”

Author(s)Urology Times staff

Casey Kowalik, MD, describes why she thinks it’s a “great time” for women to join the urology workforce. Kowalik is Assistant Professor and Associate Program Director at the University of Kansas School of Medicine Department of Urology.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Money Matters: How can you plan for your retirement income needs?

ByRonald J. Paprocki, JD, CFP, CHBC

May 29th 2026

Why RAG-based AI models may be more sufficient for patient education

ByArchan Khandekar, MD

May 26th 2026

From Washington to Rhode Island: Understanding new requirements for medical group governance

ByAmerican Association of Clinical Urology

May 25th 2026

Urology workforce stable but facing access and pipeline challenges, AUA Census finds

ByHung-Jui (Ray) Tan, MD, MSHPM

May 17th 2026

The UroOnc Minute: Emergency Hematuria Management, with Nikita R. Bhatt, MBBS, MCh, MMed, FRCS

ByAdam B. Weiner, MD,Nikita R. Bhatt, MBBS, MCh, MMed, FRCS

May 8th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

Unmet needs and emerging solutions in MRI-guided prostate cancer care

HHS requests testosterone therapy label updates, citing new safety data

Microbial dysbiosis may predict response to CBM588 in mRCC

Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC

Retrospective study suggests differences in OAB therapy persistence among older adults